How OSTHUS reduced risk in vaccine manufacturing by 6%

  • Manufacturing at risk, or before the prevalent influenza strain is known
  • Maintain vaccine effectiveness by predicting influenza variants about a year in advance
  • Prevent hospitalizations, deaths, and other costs of annual influenza viruses
  • Predictive models that use data to make quantitative influenza predictions
  • Proactive vaccine manufacturing using advanced analytics
  • Ability to manufacture vaccines ahead of the season
  • Data-driven decision-making to improve public health and disease control
  • Improved predictive accuracy by 6% and reduced manufacturing risk, subsequently saving millions of dollars per year
Michael Moskal II
Director of US Operations

Demo Title

Phase2-OSTHUS-Pop up banner

This will close in 0 seconds

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram